Cynviloq, which is marketed as Genexol-PM in South Korea, is the company’s next-generation nanoparticle paclitaxel and it completed patient enrollment in the Tribeca registrational trial in January.
Sorrento, oncology firm developing new treatments for cancer and associated pain, is also developing resiniferatoxin (RTX), a non-opiate TRPV1 agonist currently in a Phase I/II trial at the NIH to treat terminal cancer patients suffering from intractable pain.
In December 2014, Sorrento and NantWorks formed a global joint venture called Nantibody, to focus on certain next generation immunotherapies for cancer and autoimmune diseases.
Sorrento and Conkwest, a privately-held immuno-oncology company developing proprietary Neukoplast, a Natural Killer (NK) cell-line based therapy, also entered into an agreement to jointly develop next generation CAR.
The CAR.TNK technology platform combines Conkwest’s Neukoplast cell line with Sorrento’s G-MAB fully human antibody technology and CAR designs to further improve the potency and targeting of Neukoplast.
In March this year, Sorrento entered into a global collaboration with NantCell, a NantWorks company, to discover and develop new anti-cancer immunotherapies.